No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the research, development, production, and commercialization of medications, with a specific focus on endocrinology, obstetrics and gynecology, and urology. Within its animal health segment, ASKA manufactures, sells, imports, and exports a broad spectrum of veterinary products, such as medicines, medical equipment, animal feed and supplements, laboratory reagents, agricultural chemicals, industrial chemicals, hygiene products, and food items along with their raw materials. Beyond these activities, the company also performs clinical and biological testing and offers medical devices. Founded in 1920, ASKA Pharmaceutical Holdings Co.,Ltd. is headquartered in Tokyo, Japan.
www.aska-pharma-hd.co.jpNo one on the platform currently holds 4886.T.
No tracked institution reports a position in 4886.T as of their last filing.
No one on the platform has traded 4886.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.5% | 7.2% | 5.9% | — | — | — |
| Rev. Growth % | 10.9% | 5.2% | ||||
| Profit Margin % | 7.6% | 8.4% | 6.3% | |||
| Free Cash Flow Margin % | 5.3% | 2.7% | 4.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $73.1B | +5.8% | $164.40 | $164.40–$164.40 | — | 1 |
| 2028 | $75.0B | +2.5% | $194.50 | $194.50–$194.50 | — | 1 |
| 2029 | $78.5B | +4.7% | $226.40 | $226.40–$226.40 | — | 1 |
| 2030 | $79.2B | +1.0% | $229.20 | $229.20–$229.20 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.19% |
| $77.5B |
| — |
| 368A.TKitazato Corporation | $1438.00 | +0.56% | $57.5B | — |
| 4554.TFuji Pharma Co., Ltd. | $1802.00 | +2.62% | $47.1B | — |
Source: Financial Modeling Prep · peers by sector/industry